Opportunities for cost reduction of current first-line WHO-recommended oral antiretroviral therapy: replacing tenofovir disoproxil fumarate with tenofovir alafenamide

Replacing tenofovir disoproxil fumarate with tenofovir alafenamide in South Africa's first-line HIV treatment regimen could reduce annual program costs by approximately 5% (around US$54 million) while maintaining clinical effectiveness, offering a feasible interim cost-saving strategy amidst declining funding.

The Gist

Imagine South Africa's HIV treatment program as a massive, well-oiled machine that has been keeping millions of people healthy for years. The current "fuel" for this machine is a specific combination of three drugs, known as TLD. It works brilliantly, but lately, the money tank is running low. With funding from international donors shrinking, the country needs to find a way to keep the machine running without burning through its cash reserves.

The authors of this paper asked a simple question: "Can we swap out one of the fuel ingredients for a cheaper, but equally effective, alternative?"

Here is the breakdown of their proposal, using some everyday analogies:

1. The Current Setup: The "TLD" Combo

Right now, the standard treatment is a three-drug cocktail:

• Dolutegravir (The heavy lifter)
• Lamivudine (The support act)
• Tenofovir Disoproxil Fumarate (TDF) (The backbone)

This combo has been a public health hero. It's like a reliable, trusted brand of sneakers that everyone wears. However, the "TDF" part of the shoe is getting expensive to manufacture and has some side effects on the kidneys and bones over the long term.

2. The Proposed Swap: Introducing "TAF"

The researchers suggest swapping the TDF ingredient for a newer version called Tenofovir Alafenamide (TAF).

Think of TDF and TAF as two different models of the same car engine. They both get you to the same destination (keeping the virus suppressed) and have similar safety records regarding the virus itself. However:

• TDF is like an older, bulkier engine. It requires a lot of raw material to build and puts a bit more strain on the car's suspension (the kidneys and bones).
• TAF is like a newer, high-tech engine. It's smaller, lighter, and more efficient. It uses less raw material to make, which means it could be cheaper to produce. It also puts less strain on the suspension.

3. The Cost Savings: "Buying in Bulk"

The study ran the numbers for the years 2026 to 2030. Here is what they found:

• The Price Tag: Because TAF is more efficient (it needs a smaller dose) and can be made by generic manufacturers at a lower price, the drug itself is cheaper.
• The "Switch" Cost: Switching from TDF to TAF is easy. It's not like changing the entire car model (which would require new training, new tests, and new paperwork). It's more like swapping the tires on a car you already own. The drivers (patients) and mechanics (doctors) don't need to relearn how to drive.
• The Savings: If South Africa switches everyone to this new combo (called TAFLD), they could save about $54 million a year.
  • Analogy: Imagine a family of six that spends $100 a week on groceries. If they find a way to buy the exact same quality food for $95 a week, they save $5. Over a year, that's $260. Now, imagine doing that for 6 million people. That's the kind of savings we are talking about.

4. The "Bonus" Savings: Skipping the Check-up

There is a second potential saving. Because TDF can be hard on the kidneys, patients currently have to get regular blood tests to check their kidney function.

• The Theory: Since TAF is gentler on the kidneys, doctors might not need to order those specific blood tests as often.
• The Catch: The study says even if they do keep doing the blood tests, the program still saves money. But if they stop the tests, they save an extra $12 million a year.

5. The "But..." (The Fine Print)

Every story has a twist. The authors are careful to point out a few things:

• The Weight Issue: While TAF is better for kidneys, some studies suggest it might cause a bit more weight gain and changes in cholesterol compared to TDF. It's like a car that gets better gas mileage but might make the driver gain a few pounds. The long-term health costs of this weight gain are still being figured out.
• The Future: This isn't a permanent fix. The medical world is working on "long-acting" treatments (like a monthly injection instead of a daily pill). This switch to TAF is just a "bridge" to get us to that future while saving money today.
• The Supply Chain: This plan only works if enough generic factories can ramp up production quickly to meet the demand.

The Bottom Line

The paper concludes that swapping the old drug ingredient for the new one is a smart financial move. It's like upgrading your home insulation: it costs a little to switch, but it lowers your monthly bills significantly without making your house less comfortable.

For South Africa, facing tight budgets, this switch offers a way to keep the HIV treatment machine running smoothly, save tens of millions of dollars, and potentially reduce the strain on patients' kidneys, all while waiting for the next big breakthrough in HIV medicine.

Technical Summary

1. Problem Statement

South Africa's HIV treatment program, which serves over 6 million people, faces severe financial strain exacerbated by recent funding cuts from the United States Government (USG). The current first-line regimen, TLD (Tenofovir Disoproxil Fumarate + Lamivudine + Dolutegravir), has been highly effective but requires cost optimization to ensure sustainability.

• The Dilemma: While next-generation long-acting agents are under investigation, they are not expected to replace oral regimens for at least a decade.
• The Gap: There is a need to identify immediate cost-saving opportunities within the existing WHO-recommended framework without compromising clinical efficacy or safety.
• The Proposed Solution: The authors investigate replacing Tenofovir Disoproxil Fumarate (TDF) with Tenofovir Alafenamide (TAF) in the first-line regimen (creating TAFLD). TAF is a newer prodrug with a lower dose requirement (25mg vs. 300mg), potentially lower manufacturing costs, and a more favorable renal/bone safety profile, though it is associated with weight gain and lipid changes.

2. Methodology

The study employed a budget-impact analysis from the provider perspective (South African government) covering the period 2026–2030.

• Costing Approach: Ingredients-based costing was used to estimate the full cost of ART provision per patient-year at a general primary health clinic (PHC).
  • Cost Components: Drug ingredients, laboratory monitoring (viral load, CD4, creatinine), staff time/cadre, consumables, equipment, and overheads.
  • Price Inputs:
    • TLD: Weighted average price of US$4.17 per 28 tablets (based on current government procurement).
    • TAFLD: Estimated at US$3.64 per 28 tablets based on discussions with two generic manufacturers.
  • Currency: All costs reported in 2025 US dollars (undiscounted, non-inflated).
• Population Modeling:
  • Used Thembisa 4.8 to estimate the number of adults (15+) on first-line therapy.
  • Assumed a phased transition over two years: 50% switch by end-2026 and 100% switch by end-2027.
• Scenarios Analyzed:
  1. Base Case: Full replacement of TDF with TAF, assuming creatinine monitoring is removed (due to TAF's better renal profile).
  2. Sensitivity 1: TAFLD price variation (±15%).
  3. Sensitivity 2: Retention of creatinine monitoring for TAFLD patients (to test robustness if guidelines do not change).

3. Key Contributions

• Economic Modeling of Regimen Switching: This is one of the first studies to quantify the budget impact of switching the backbone of the first-line ART regimen in a large-scale, high-burden setting like South Africa.
• Operational Feasibility: The study highlights that unlike previous transitions (e.g., Stavudine to TDF or Efavirenz to Dolutegravir), switching TDF to TAF requires no additional laboratory monitoring (if creatinine is dropped) and minimal patient counseling, as the side effect profiles are generally similar regarding tolerability.
• Environmental & Supply Chain Insight: The authors note that TAF's lower dose (25mg) reduces Active Pharmaceutical Ingredient (API) usage, potentially lowering manufacturing costs, packaging requirements, and the environmental carbon footprint.

4. Results

The analysis indicates that replacing TDF with TAF yields significant cost savings:

• Per-Patient Savings:
  • First Year of ART: Costs decrease from $287 (TLD) to $277 (TAFLD).
  • Follow-up Years: Costs decrease from $178 (TLD) to $169 (TAFLD).
  • This represents a 4–5% reduction in annual per-patient costs.
• Program-Level Savings (2026–2030):
  • At full replacement, the program saves approximately US$54 million annually (a 5% reduction in total first-line treatment costs).
  • Total 5-year costs for TLD are projected at $1,063–$1,163 million, whereas TAFLD reduces this to $1,031–$1,080 million.
• Impact of Creatinine Monitoring:
  • Even if creatinine monitoring is retained for TAFLD patients (adding ~$12 million/year in testing costs), the program still achieves a 4% annual cost reduction ($50 million savings).
• Price Sensitivity:
  • If TAFLD prices drop by an additional 15%, savings increase to 8%.
  • If TAFLD prices rise by 15%, the regimen becomes marginally more expensive (+0.1%) than TLD.

5. Significance and Limitations

Significance:

• Fiscal Sustainability: In an era of shrinking global health funding, a 5% reduction in the largest line item of the HIV budget (ART drugs and provision) is critical for maintaining treatment coverage.
• Strategic Interim Step: The authors position TAFLD as a feasible "interim" cost-reduction strategy while waiting for next-generation long-acting therapies.
• Clinical Trade-offs: The study acknowledges the trade-off between TDF's renal/bone toxicity and TAF's association with weight gain and lipid changes. However, it argues that in the absence of robust long-term African data on these metabolic effects, the immediate fiscal necessity and the ability to drop creatinine monitoring make TAFLD a viable option.

Limitations:

• Data Gaps: The model relies on assumptions about generic manufacturing capacity and pricing, which may fluctuate.
• Long-term Health Costs: The analysis does not factor in the potential long-term costs of TAF-associated weight gain and metabolic syndrome, nor does it fully quantify the long-term savings from avoiding TDF-associated renal failure.
• Data Systems: The accuracy of population projections is impacted by the loss of PEPFAR-supported data systems in South Africa.

Conclusion:
The paper concludes that replacing TDF with TAF in South Africa's first-line regimen is a cost-saving strategy that can generate ~$54 million in annual savings with minimal programmatic disruption. It represents a pragmatic approach to maintaining treatment access amidst funding constraints, provided that policymakers carefully weigh the metabolic risks against the renal benefits and fiscal realities.